<VariationArchive RecordType="classified" VariationID="1070849" VariationName="NC_000023.10:g.(?_153647872)_(153650075_?)del" VariationType="Deletion" Accession="VCV001070849" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-03-26" DateCreated="2021-05-10" MostRecentSubmission="2023-03-26">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1058208" VariationID="1070849">
      <GeneList>
        <Gene Symbol="TAFAZZIN" FullName="tafazzin, phospholipid-lysophospholipid transacylase" GeneID="6901" HGNC_ID="HGNC:11577" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>Xq28</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="154411539" stop="154421726" display_start="154411539" display_stop="154421726" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="153639876" stop="153650064" display_start="153639876" display_stop="153650064" Strand="+" />
          </Location>
          <OMIM>300394</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000023.10:g.(?_153647872)_(153650075_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xq28</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" innerStart="153647872" innerStop="153650075" display_start="153647872" display_stop="153650075" variantLength="2204" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.(?_153647872)_(153650075_?)del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.(?_153647872)_(153650075_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000023.10:g.(?_153647872)_(153650075_?)del AND 3-Methylglutaconic aciduria type 2" Accession="RCV001383140" Version="2">
        <ClassifiedConditionList TraitSetID="3071">
          <ClassifiedCondition DB="MedGen" ID="C0574083">3-Methylglutaconic aciduria type 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-08-04" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-08-04" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-05-10" MostRecentSubmission="2023-03-26">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">23656970</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3071" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="487" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Barth syndrome</ElementValue>
                <XRef ID="MONDO:0010543" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">3-methylglutaconicaciduria type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MGA type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cardioskeletal myopathy with neutropenia and abnormal mitochondria</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">3-Methylglutaconic aciduria type 2</ElementValue>
                <XRef ID="Barth+Syndrome/744" DB="Genetic Alliance" />
                <XRef ID="297231002" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MGCA2</ElementValue>
                <XRef Type="MIM" ID="302060" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">BTHS</ElementValue>
                <XRef Type="MIM" ID="302060" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MGA2</ElementValue>
                <XRef Type="MIM" ID="302060" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Barth syndrome is characterized in affected males by cardiomyopathy, neutropenia, skeletal myopathy, prepubertal growth delay, and distinctive facial gestalt (most evident in infancy); not all features may be present in a given affected male. Cardiomyopathy, which is almost always present before age five years, is typically dilated cardiomyopathy with or without endocardial fibroelastosis or left ventricular noncompaction; hypertrophic cardiomyopathy can also occur. Heart failure is a significant cause of morbidity and mortality; risk of arrhythmia and sudden death is increased. Neutropenia is most often associated with mouth ulcers, pneumonia, and sepsis. The nonprogressive myopathy predominantly affects the proximal muscles, and results in early motor delays. Prepubertal growth delay is followed by a postpubertal growth spurt with remarkable "catch-up" growth. Heterozygous females who have a normal karyotype are asymptomatic and have normal biochemical studies.</Attribute>
                <XRef ID="NBK247162" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5890" />
                <XRef ID="5890" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301486</ID>
                <ID Source="BookShelf">NBK1309</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">25299040</ID>
                <ID Source="BookShelf">NBK247162</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C5-OH.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated C5-OH Acylcarnitine, Organic Acidemias, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C5-OH-Elevated.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Organic Acidemias: Elevated C5-OH, 2022</CitationText>
              </Citation>
              <XRef ID="111" DB="Orphanet" />
              <XRef ID="C0574083" DB="MedGen" />
              <XRef ID="MONDO:0010543" DB="MONDO" />
              <XRef Type="MIM" ID="302060" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3107789" SubmissionDate="2023-03-21" DateLastUpdated="2023-03-26" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="NM_000116.4_X_Deletion (exons 6-11)|MedGen:C0574083" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001582167" DateUpdated="2023-03-26" DateCreated="2021-05-10" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-08-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">23656970</ID>
          </Citation>
          <Comment>This variant is a gross deletion of the genomic region encompassing exon(s) 6-11 of the TAZ gene. The 5' boundary is likely confined to intron 5. The 3' end of this event is unknown as it extends through the termination codon beyond the assayed region for this gene and may encompass additional genes. While this deletion is not anticipated to lead to nonsense mediated decay, it is expected to alter mRNA translation or result in a truncated protein product. A similar copy number variant has been observed in individual(s) with Barth syndrome (PMID: 23656970). In at least one individual the variant was observed to be de novo. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TAFAZZIN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.10:g.(?_153647872)_(153650075_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0574083" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12974844</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3107789" TraitType="Disease" MappingType="XRef" MappingValue="C0574083" MappingRef="MedGen">
        <MedGen CUI="C0574083" Name="3-Methylglutaconic aciduria type 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

